Literature DB >> 24581453

Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application.

Stefan Leucht1.   

Abstract

Different definitions of response, remission, and recovery are used in schizophrenia research, which makes comparing and applying results in clinical practice difficult. Response criteria are often based on reductions in rating scale scores (eg, ≥ 20% reduction from baseline). However, when reduction scores from rating scales, such as the Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS), are linked to Clinical Global Impressions (CGI) scores, which are more easily understood, rating scale scores have better clinical application. This linking process also reveals that the widely used response cutoff of 20% does not reflect clinically meaningful improvement in patients with acute, nonrefractory schizophrenia. This article provides suggestions for selecting response criteria, displaying responder rates, and using standard definitions (eg, remission, recovery) in research studies. The ultimate goal of recovery in schizophrenia treatment includes sustained symptom resolution and a return to full functioning. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24581453     DOI: 10.4088/JCP.13049su1c.02

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  32 in total

1.  The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.

Authors:  Søren D Østergaard; Leslie Foldager; Ole Mors; Per Bech; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

2.  A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.

Authors:  Christian Schmidt-Kraepelin; Sandra Feyerabend; Christina Engelke; Mathias Riesbeck; Eva Meisenzahl-Lechner; Wolfgang Gaebel; Pablo-Emilio Verde; Henrike Kolbe; Christoph U Correll; Stefan Leucht; Stephan Heres; Michael Kluge; Christian Makiol; Andrea Neff; Christina Lange; Susanne Englisch; Mathias Zink; Berthold Langguth; Timm Poeppl; Dirk Reske; Euphrosyne Gouzoulis-Mayfrank; Gerhard Gründer; Alkomiet Hasan; Anke Brockhaus-Dumke; Markus Jäger; Jessica Baumgärtner; Thomas Wobrock; Joachim Cordes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-09-05       Impact factor: 5.270

3.  Treatment of auditory hallucinations with bilateral theta burst stimulation (cTBS): protocol of a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Christian Plewnia; Bettina Brendel; Tobias Schwippel; Peter Martus; Joachim Cordes; Alkomiet Hasan; Andreas J Fallgatter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-12-09       Impact factor: 5.270

4.  How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials.

Authors:  Myrto T Samara; Adriani Nikolakopoulou; Georgia Salanti; Stefan Leucht
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

5.  Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies.

Authors:  Ilja Spellmann; Rebecca Schennach; Florian Seemüller; Sebastian Meyer; Richard Musil; Markus Jäger; Max Schmauß; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Michael Bauer; Mazda Adli; Joachim Zeiler; Wolfram Bender; Klaus-Thomas Kronmüller; Marcus Ising; Peter Brieger; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Michael Riedel; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-26       Impact factor: 5.270

6.  Negative symptoms in first episode schizophrenia: treatment response across the 2-year follow-up of the "Parma Early Psychosis" program.

Authors:  Lorenzo Pelizza; Emanuela Leuci; Davide Maestri; Emanuela Quattrone; Silvia Azzali; Giuseppina Paulillo; Pietro Pellegrini
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-01-28       Impact factor: 5.270

7.  Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial.

Authors:  Itxaso González-Ortega; Enrique Echeburúa; Susana Alberich; Miguel Bernardo; Eduard Vieta; Gonzalo Salazar de Pablo; Ana González-Pinto
Journal:  Int J Environ Res Public Health       Date:  2022-06-15       Impact factor: 4.614

8.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.

Authors:  Paolo Fusar-Poli; Evangelos Papanastasiou; Daniel Stahl; Matteo Rocchetti; William Carpenter; Sukhwinder Shergill; Philip McGuire
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

Review 9.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Authors:  Oliver D Howes; Rob McCutcheon; Ofer Agid; Andrea de Bartolomeis; Nico J M van Beveren; Michael L Birnbaum; Michael A P Bloomfield; Rodrigo A Bressan; Robert W Buchanan; William T Carpenter; David J Castle; Leslie Citrome; Zafiris J Daskalakis; Michael Davidson; Richard J Drake; Serdar Dursun; Bjørn H Ebdrup; Helio Elkis; Peter Falkai; W Wolfgang Fleischacker; Ary Gadelha; Fiona Gaughran; Birte Y Glenthøj; Ariel Graff-Guerrero; Jaime E C Hallak; William G Honer; James Kennedy; Bruce J Kinon; Stephen M Lawrie; Jimmy Lee; F Markus Leweke; James H MacCabe; Carolyn B McNabb; Herbert Meltzer; Hans-Jürgen Möller; Shinchiro Nakajima; Christos Pantelis; Tiago Reis Marques; Gary Remington; Susan L Rossell; Bruce R Russell; Cynthia O Siu; Takefumi Suzuki; Iris E Sommer; David Taylor; Neil Thomas; Alp Üçok; Daniel Umbricht; James T R Walters; John Kane; Christoph U Correll
Journal:  Am J Psychiatry       Date:  2016-12-06       Impact factor: 18.112

Review 10.  Increasing antipsychotic dose for non response in schizophrenia.

Authors:  Myrto T Samara; Elisabeth Klupp; Bartosz Helfer; Philipp H Rothe; Johannes Schneider-Thoma; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2018-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.